Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Corporate Update

24 Nov 2022 07:00

RNS Number : 4245H
DeepMatter Group PLC
24 November 2022
 

 

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 16 APRIL 2014 ON MARKET ABUSE (MARKET ABUSE REGULATION) AS RETAINED AS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED.

UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

24 November 2022

DeepMatter Group Plc

 

Corporate Update

DeepMatter Group Plc (AIM: DMTR, "Deepmatter", the "Group" or the "Company"), the digital chemistry data and software company, today announces that it has been in discussions with its major shareholders and potential institutional investors in relation to securing capital to fund the future working capital requirements of the Group.

 

Following these discussions, the board of directors (the "Board") have concluded that the cancellation of trading in the Company's ordinary shares on AIM (the "Cancellation") and subsequent re-registration as a private limited company ("the Re-registration", together with Cancellation the "Delisting") will provide greater opportunities to raise additional capital. This view has been supported to date by major shareholders.

 

In reaching this conclusion the Board has considered the interests of the Company's shareholders as a whole and, in doing so, has had regard for its wider stakeholders.

 

Any Delisting would be conditional on shareholder approval and there can be no certainty that proposals for a Delisting will be approved. The Board intends to continue discussions with key stakeholders on the Delisting and a further announcement will be made in due course.

 

The Company anticipates it will seek to raise c.£1m from its major shareholders ahead of the Delisting, following which a more substantial capital raise would be pursued as a private limited company in 2023. This capital raise is being undertaken in order to fund the long term growth ambitions of the Company.

 

The Group continues to expect revenue for the current financial year to be no less than £1.5m and the Group has cash and short term receivables of £0.7m.

 

For more information contact

 

DeepMatter Group Plc 0141 548 8156 Fraser Benson, Chief Financial Officer

Canaccord Genuity Limited (Nominated Advisor and Broker) 020 7523 8000Bobbie Hilliam

 

Meare Consulting 07990 858548Adrian Duffield

About DeepMatter Group plc 

 

DeepMatter's SmartChemistry™ platform enables scientists across a range of industries, including pharma, biotech, agri-science, scientific publishers and contract research organisations (CROs), to easily capture, access and exploit the vast amounts of data created in chemical reactions.

 

DeepMatter integrates its proprietary chemistry data and proprietary software to significantly improve productivity, efficiency, discovery, safety and sustainability of chemical reactions for its customers.

 

DeepMatter's SmartChemistry™ platform capitalises on the combination of its cloud technology, low cost-sensors, connectivity to laboratory hardware and high-performance computing trends such as artificial intelligence (AI).

 

Visit: www.deepmatter.io and follow @deepmattergroup

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDDGBDBRSDDGDX
Date   Source Headline
24th Jan 20228:50 amRNSHolding(s) in Company
24th Jan 20227:00 amRNSHolding(s) in Company
20th Jan 202212:15 pmRNSResult of General Meeting
20th Jan 20227:00 amRNSResult of Open Offer - Correction
19th Jan 202211:30 amRNSResult of Open Offer
4th Jan 20221:30 pmRNSPosting of Circular and Notice of GM
29th Dec 20214:36 pmRNSPrice Monitoring Extension
24th Dec 20217:00 amRNSPlacing, Subscription and Open Offer
17th Dec 20215:00 pmRNSBusiness Update and Financing
22nd Oct 20217:00 amRNSAppointment of new Scientific Advisory Board
21st Oct 20218:00 amRNSDigitalGlassware® platform trial with Aurigene
28th Sep 20217:00 amRNSCollaboration
22nd Sep 20217:00 amRNSHalf Year Results
14th Sep 202110:30 amRNSNotice of Half Year Results
8th Sep 20211:30 pmRNSHolding(s) in Company
18th Aug 20217:00 amRNSAdvisory Board Appointment
5th Aug 20217:00 amRNSCollaboration with the University of Cambridge
12th Jul 20217:00 amRNSAppointment of Non-Executive Director
30th Jun 20213:34 pmRNSResult of AGM
22nd Jun 20217:00 amRNSChanges to 2021 AGM Arrangements
17th Jun 20217:00 amRNSCollaboration with the University of Leeds
8th Jun 20213:16 pmRNSPosting of ARA and Updated Notice of AGM
1st Jun 20217:00 amRNSFinal Results
24th May 20217:00 amRNSNotice of Results and Investor Presentation
6th May 20213:43 pmRNSHolding(s) in Company
7th Apr 20217:00 amRNSCollaboration with the University of Nottingham
11th Mar 20217:00 amRNSCo-distribution agreement with Elemental Machines
9th Mar 20217:00 amRNSDirectorate Change
20th Jan 20217:00 amRNSAgreement with Merck's Life Sciences business
19th Jan 20217:00 amRNSHolding(s) in Company
8th Jan 20212:00 pmRNSPrice Monitoring Extension
18th Dec 202010:30 amRNSGrant of PDMR Options
17th Dec 20207:00 amRNSMulti-year contract with Thieme Chemistry
26th Oct 202011:05 amRNSSecond Price Monitoring Extn
26th Oct 202011:00 amRNSPrice Monitoring Extension
21st Oct 20207:00 amRNSIssue of Shares and Total Voting Rights
19th Oct 20207:00 amRNSDirectorate Changes
16th Oct 20207:00 amRNSStrong adoption of ICSYNTH
2nd Oct 20202:05 pmRNSSecond Price Monitoring Extn
2nd Oct 20202:00 pmRNSPrice Monitoring Extension
1st Oct 20208:00 amRNSGrant of Options
29th Sep 20207:00 amRNSHolding(s) in Company
23rd Sep 20201:40 pmRNSHolding(s) in Company
22nd Sep 20204:29 pmRNSHolding(s) in Company
22nd Sep 20204:00 pmRNSHolding(s) in Company
22nd Sep 202010:32 amRNSHolding(s) in Company
15th Sep 20208:08 amRNSIssue of Shares and Total Voting Rights
10th Sep 20207:00 amRNSHalf-year Report
4th Sep 20208:26 amRNSHolding(s) in Company
3rd Sep 20207:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.